OTCMKTS:VXRT Vaxart (VXRT) Stock Price, News & Analysis $0.36 0.00 (0.00%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsNews and TrendsSEC Filings About Vaxart Stock (OTCMKTS:VXRT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vaxart alerts:Sign Up Key Stats Today's Range$0.35▼$0.3750-Day Range$0.36▼$0.5052-Week Range$0.33▼$0.84Volume245,774 shsAverage Volume297,552 shsMarket Capitalization$86.51 millionP/E Ratio2.73Dividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Vaxart, Inc. is a clinical-stage biotechnology company developing oral vaccines for infectious diseases. Its proprietary platform is designed to deliver vaccine candidates in tablet form and to stimulate immune responses at mucosal surfaces as well as throughout the body. The company’s investigational programs have included vaccines for norovirus, seasonal influenza and COVID-19. These candidates remain in development and are not approved vaccines. Based in South San Francisco, California, Vaxart focuses on research and development and may work with external partners to advance its vaccine programs.AI Generated. May Contain Errors. Read More Vaxart Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreVXRT MarketRank™: 1.13172920065 of 5 starsVaxart scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingVaxart has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVaxart has received no research coverage in the past 90 days.Read more about Vaxart's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Vaxart are expected to decrease in the coming year, from ($0.68) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxart is 2.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.33.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxart is 2.73, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.19.Price to Book Value per Share RatioVaxart has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.02% of the float of Vaxart has been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 3.95, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vaxart has recently increased by 0.54%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVaxart does not currently pay a dividend.Dividend GrowthVaxart does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentVaxart has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Vaxart this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for VXRT on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows4 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vaxart insiders have not sold or bought any company stock.Percentage Held by Insiders2.80% of the stock of Vaxart is held by insiders.Percentage Held by Institutions18.05% of the stock of Vaxart is held by institutions.Read more about Vaxart's insider trading history. Receive VXRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VXRT Stock News HeadlinesVaxart Earnings Call Highlights Progress and Funding RisksNovember 14, 2026 | tipranks.comVaxart Provides Business Update and Reports Third Quarter 2026 Financial ResultsNovember 5, 2026 | tmcnet.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 18 at 1:00 AM | Behind the Markets (Ad)Vaxart to Host Stockholder Fireside Chat on November 6 at 4:30 p.m. ETOctober 29, 2026 | finance.yahoo.comVaxart to Host Stockholder Fireside Chat on November 6 at 4:30 p.m. ETOctober 29, 2026 | globenewswire.comVaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of DirectorsOctober 19, 2026 | finance.yahoo.comVaxart's VXA-H5-02 Shows 100% Survival In H5N1 Ferret StudyOctober 8, 2026 | rttnews.comVaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge ModelOctober 8, 2026 | finance.yahoo.comSee More Headlines VXRT Stock Analysis - Frequently Asked Questions How have VXRT shares performed this year? Vaxart's stock was trading at $0.3464 at the beginning of 2026. Since then, VXRT shares have increased by 2.5% and is now trading at $0.3550. How were Vaxart's earnings last quarter? Vaxart, Inc. (OTCMKTS:VXRT) released its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.04. The biotechnology company earned $10.62 million during the quarter, compared to the consensus estimate of $27.20 million. Vaxart had a net margin of 16.02% and a trailing twelve-month return on equity of 35.14%. Read the conference call transcript. When did Vaxart's stock split? Vaxart shares reverse split before market open on Wednesday, February 14th 2018.The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. How do I buy shares of Vaxart? Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxart investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), Sorrento Therapeutics (SRNE), Novavax (NVAX), NIO (NIO), Tesla (TSLA) and NVIDIA (NVDA). Company Calendar Last Earnings11/05/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:VXRT Previous SymbolNASDAQ:NABI CIK72444 Webwww.vaxart.com Phone(650) 550-3500Fax650-871-8580Employees65Year Founded2004Profitability EPS (Trailing Twelve Months)$0.13 Trailing P/E Ratio2.73 Forward P/E RatioN/A P/E GrowthN/ANet Income$16.33 million Net Margins16.02% Pretax Margin16.42% Return on Equity35.14% Return on Assets17.10% Debt Debt-to-Equity RatioN/A Current Ratio1.71 Quick Ratio1.71 Sales & Book Value Annual Sales$237.26 million Price / Sales0.36 Cash Flow$0.10 per share Price / Cash Flow3.47 Book Value$0.27 per share Price / Book1.31Miscellaneous Outstanding Shares243,700,000Free Float236,879,000Market Cap$86.51 million OptionableNo Data Beta1.15 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (OTCMKTS:VXRT) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.